secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001628280-26-015159
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum reports Q4 2025 net loss of $15.2M; upsizes ATM to $100M; Phase 2 IPF trial dosed
--------------------------------------------------------------------------------

- Net loss of $15.2M vs $14.6M in Q4 2024; R&D expenses $12.8M, G&A $4.4M.
- Cash and equivalents $262.9M; cash runway projected through mid-2029.
- Initiated dosing in PROPEL-IPF Phase 2 trial of PIPE-791 for IPF (324 patients).
- Amended ATM sales agreement to offer up to $100M in common stock; lock-up until March 11, 2026.
- Topline data from PIPE-791 Phase 1b chronic pain trial expected Q2 2026; J&J Phase 2 MDD trial recruiting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/0001628280-26-015159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/ctnm-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-015159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer